Stocktoria

SOLIGENIX, INC. SNGX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1994-04-04 · LEI

SOLIGENIX, INC. financials (annual)

Revenue
$10.4M $5.4M $5.2M $4.6M $2.4M $824268 $948911 $839359 $119371 2016201720182019202020212022202320242025
Net income
-$3.2M -$7.1M -$8.9M -$9.4M -$17.7M -$12.6M -$13.8M -$6.1M -$8.3M -$11.1M 2016201720182019202020212022202320242025
Free cash flow
-$10.3M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$119,371$839,359$948,911$824,268$2.4M$4.6M$5.2M$5.4M$10.4M
Gross profit$97,311$398,089$95,628$538,498$1.1M$643,733$1.1M$2.0M
R&D expense$7.5M$5.2M$3.3M$7.9M$8.2M$9.8M$8.1M$6.8M$5.5M$4.3M
Operating income-$11.8M-$9.4M-$7.7M-$14.2M-$13.1M-$18.6M-$10.5M-$9.1M-$7.6M-$5.7M
Income tax-$506,615-$409,114-$1.8M-$1.2M-$864,742-$836,893-$610,676-$416,810-$530,143
Net income-$11.1M-$8.3M-$6.1M-$13.8M-$12.6M-$17.7M-$9.4M-$8.9M-$7.1M-$3.2M
EPS (diluted)$-2.14$-4.98$-12.66$-4.81$-4.69$-0.64$-1.16$-1.34
Operating cash flow-$10.3M-$8.4M-$8.6M-$12.6M-$11.7M-$11.5M-$7.5M-$7.2M-$6.5M-$5.0M
Free cash flow-$10.3M
Cash & equivalents$26.0M$18.7M$5.4M$9.0M$7.8M$8.8M
Total assets$9.2M$9.0M$9.8M$14.3M$26.9M$19.9M$7.8M$10.5M$9.5M$10.3M
Total liabilities$3.9M$4.8M$7.3M$16.8M$16.1M$16.1M$6.3M$4.2M
Shareholders' equity$5.3M$4.1M$2.5M-$2.5M$10.7M$3.7M$1.5M$6.3M$6.3M$7.4M

Growth · year-over-year · Revenue CAGR -42.8%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-85.8%-11.5%+15.1%-65.1%-49.0%-11.7%-3.5%-48.0%+19.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.